Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22541335 | 0.90 | KMT2A (0.42) | KMT2ANPC1RAB9ACNR2KDM4E | |
| SCHEMBL22291908 | 0.84 | DPP4 (0.44) | KMT2ANPC1RAB9ACNR2KDM4E | |
| SCHEMBL22291930 | 0.83 | KMT2A (0.45) | KMT2ANPC1RAB9ACNR2KDM4E | |
| SCHEMBL22541332 | 0.83 | KMT2A (0.45) | KMT2ANPC1RAB9ACNR2KDM4E | |
| SCHEMBL28097962 | 0.81 | KDM4E (0.50) | KMT2ARAB9ACNR2KDM4ETSHR | |
| SCHEMBL22541269 | 0.81 | SMN1; SMN2 (0.44) | KMT2ANPC1RAB9ACNR2KDM4E | |
| SCHEMBL18269741 | 0.81 | CNR2 (0.40) | KMT2ANPC1RAB9ACNR2KDM4E | |
| Bromide SCHEMBL16949900 | 0.79 | KDM4E (0.49) | RAB9ACNR2KDM4ETSHRALDH1A1 | |
| SCHEMBL22291937 | 0.77 | KDM4E (0.48) | KMT2ANPC1RAB9ACNR2KDM4E | |
| SCHEMBL20507402 | 0.76 | TNF (0.45) | KMT2AKDM4ECRBNALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118806753-B | Application of isoindolone compounds in preparation of antiviral drugs | 中国医学科学院医药生物技术研究所 | 2025-02-07 | — | — | CN | claimed |
| CN-118806753-A | Application of isoindolone compounds in preparation of antiviral drugs | 中国医学科学院医药生物技术研究所 | 2024-10-22 | — | — | CN | claimed |
| CN-118806753-B | Application of isoindolone compounds in preparation of antiviral drugs | 中国医学科学院医药生物技术研究所 | 2025-02-07 | — | — | CN | disclosed |
| CN-118806753-A | Application of isoindolone compounds in preparation of antiviral drugs | 中国医学科学院医药生物技术研究所 | 2024-10-22 | — | — | CN | disclosed |
| US-20210047267-A1 | THALIDOMIDE ANALOGS AND METHODS OF USE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-18 | — | — | US | disclosed |
| US-10836721-B2 | Thalidomide analogs and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200325102-A1 | THALIDOMIDE ANALOGS AND METHODS OF USE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-10-15 | — | — | US | disclosed |
| US-10730835-B2 | Thalidomide analogs and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, HEALTH AND HUMAN SERVICES (US) | 2020-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836721-B2 | Thalidomide analogs and methods of use | PGF, TYMP, TPMT | KMT2A 1499/4885NPC1 4875/4885RAB9A 4386/4885 |
| US-10730835-B2 | Thalidomide analogs and methods of use | PGF, TYMP, TPMT | KMT2A 1499/4885NPC1 4875/4885RAB9A 4386/4885 |
| US-20210047267-A1 | THALIDOMIDE ANALOGS AND METHODS OF USE | PGF, TYMP, TPMT | KMT2A 1499/4885NPC1 4875/4885RAB9A 4386/4885 |
| US-20200325102-A1 | THALIDOMIDE ANALOGS AND METHODS OF USE | PGF, TYMP, TPMT | KMT2A 1499/4885NPC1 4875/4885RAB9A 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.